CTBO (Cantabio Pharmaceuticals) EBIT: $-0.33 Mil (TTM As of Dec. 2018)


What is Cantabio Pharmaceuticals EBIT?

Cantabio Pharmaceuticals CTBO EBIT is $-0.33 Mil as of Dec. 2018.

Cantabio Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2018 was $0.69 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.33 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cantabio Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2018 was -62.97%. Cantabio Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cantabio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2018 was -1,655.00%.

Cantabio Pharmaceuticals  (OTCPK:CTBO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cantabio Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2018 is calculated as:

ROC % (Q: Dec. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2018 ) + Invested Capital (Q: Dec. 2018 ))/ count )
=-0.96 * ( 1 - 0% )/( (1.64 + 1.409)/ 2 )
=-0.96/1.5245
=-62.97 %

where

Invested Capital(Q: Sep. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.022 - 0.804 - ( 0.022 - max(0, 2.444 - 0.022+0.022))
=1.64

Invested Capital(Q: Dec. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.326 - 0.806 - ( 0.283 - max(0, 2.215 - 0.326+0.283))
=1.409

Note: The Operating Income data used here is four times the quarterly (Dec. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Cantabio Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2018  Q: Dec. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2.76/( ( (0 + max(-0.803, 0)) + (0 + max(-0.763, 0)) )/ 2 )
=2.76/( ( 0 + 0 )/ 2 )
=2.76/0
= %

where Working Capital is:

Working Capital(Q: Sep. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.804 + 0 + -0.0010000000000003)
=-0.803

Working Capital(Q: Dec. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.043) - (0.806 + 0 + 0)
=-0.763

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cantabio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2018 )
=-0.331/0.020
=-1,655.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals EBIT Related Terms

Cantabio Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals EBIT Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
EBIT
Get a 7-Day Free Trial -0.09 -0.03 -0.75 -1.07 -1.39

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.62 -0.12 -0.28 0.69

CTBO vs TNTY, ETNI, NTRR: EBIT Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's EV-to-EBIT falls into.


Cantabio Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.33 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a EBIT of $-0.33 Mil as of Dec. 2018. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cantabio Pharmaceuticals.
Is Cantabio Pharmaceuticals' EBIT too high?
Cantabio Pharmaceuticals' current EBIT is $-0.33 Mil.
How does Cantabio Pharmaceuticals' EBIT compare to TNTY and ETNI?
Cantabio Pharmaceuticals' EBIT of $-0.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cantabio Pharmaceuticals. Cantabio Pharmaceuticals's current EBIT is $-0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current EBIT of $-0.33 Mil. The current EBIT is $-0.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current EBIT is $-0.33 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.